Anpheros Search · Treatment

Florbetaben (18F)

Also known as: florbetaben (18f) · Neuraceq

General information only. Anpheros does not diagnose and does not recommend treatment. Talk to a doctor or pharmacist about your situation. In an emergency, call 112 (or your local emergency number).

In short

Florbetaben (18F) is a diagnostic radiopharmaceutical indicated in the European Union for Positron Emission Tomography (PET) imaging of beta-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive impairment. It is used in conjunction with a clinical evaluation, and a negative scan indicates sparse or no plaques, which is not consistent with a diagnosis of Alzheimer's disease. The medicine has an approved indication for the condition of Alzheimer's disease.

Source: European Medicines Agency (EMA), Neuraceq — EPAR, 06/08/2026. © European Medicines Agency. · Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.

AI-generated summary of the sources cited on this page, checked automatically against them. Not reviewed by a clinician; not medical advice.

Codes

EMA
EMEA/H/C/002553

Official indications

Quoted unchanged from official product information, in English. Listed alphabetically by product, not ranked.

EMA (EU) Neuraceq

This medicinal product is for diagnostic use only. Neuraceq is a radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of ? amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment. Neuraceq should be used in conjunction with a clinical evaluation. A negative scan indicates sparse or no plaques, which is not consistent with a diagnosis of AD.

Source: European Medicines Agency (EMA), Neuraceq — EPAR, 06/08/2026. © European Medicines Agency.

Document date: 06/08/2026 · Official document →

Related terms in the cited sources

Has an official indication for

In alphabetical order.

Other treatments A–Z

What people report

Not enough data yet. Anonymous counts appear here only for groups of at least 20 people who agreed to share them.

How these counts are made →

External resources

Questions

What is Florbetaben (18F) approved for in the European Union?

This medicinal product is for diagnostic use only. Neuraceq is a radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of ? amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment. Neuraceq should be used in conjunction with a clinical evaluation. A negative scan indicates sparse or no plaques, which is not consistent with a diagnosis of AD. (Source: European Medicines Agency (EMA), Neuraceq — EPAR, 06/08/2026. © European Medicines Agency.)

Sources and attribution

  • Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.
  • Names other than the official source titles: Anpheros translations and plain-language names, made with AI assistance and checked automatically; the source names are in English.
  • This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
  • Source: European Medicines Agency (EMA), Neuraceq — EPAR, 06/08/2026. © European Medicines Agency.

Anpheros Search catalog 2026.10.5, published 17 October 2026. About the data →